Comparison of the Supraflex Cruz 60 Micron Versus the Ultimaster Tansei 80 Micron in HBR PCI Population

Inclusion criteria: Patients are eligible for inclusion into the study if the following criteria are met. * Patients of 18 years and above * Written or witnessed oral consent to participate in the study * Native coronary artery lesions eligible for PCI with stents with no restrictions in number of lesions and stents, vessel size or lesion complexity, apart from stent thrombosis. * Patients at high risk for bleeding according to the HBR ARC criteria: Patients meet the HBR ARC criteria if ≥1 major or ≥2 minor criteria are met. Major HBR criteria are the following: * Clinical indication for treatment with oral anticoagulants (OAC/NOAC) for at least 12 months * Severe or end-stage chronic kidney failure (GFR ≤ 30 ml/min) * Hemoglobin (Hb) level at screening \< 11g/dl or \< 6.8 mmol/l * Spontaneous bleeding requiring hospitalization or transfusion in the past 6 months or at any time, if recurrent * Moderate or severe baseline true thrombocytopenia (platelet count \<100 \*10\^9/L) * History of chronic bleeding diathesis, like: leukemia, haemophilia, vitamin K deficiency, Factor V or VII deficiency etc. * Liver cirrhosis with portal hypertension * Active malignancy (other than skin) within the past 12 months * Spontaneous intracranial haemorrhage ICH (at any time) * Traumatic intracranial haemorrhage ICH within 12 months * Presence of a brain arterio-venous malformation (AVM) * Moderate or severe ischemic stroke within the past 6 months * Nondeferrable major surgery on DAPT after PCI * Recent major surgery or major trauma within 30 d before PCI Minor HBR criteria are the following: * Age ≥ 75 years * Moderate chronic kidney disease (GFR \>30 and \<60 ml/min) * Hemoglobin (Hb) 11-12.9 g/dL / 6.8-8.0 mmol/l for men and 11-11.9 g/dL / 6.8-7.4 mmol/l for women * Any ischemic stroke at any time not meeting the major criterion * Spontaneous bleeding requiring hospitalization or transfusion within the past 12 months * Need for chronic treatment with steroids or non-steroidal anti-inflammatory drugs Exclusion criteria: Patients are not eligible if any of the following applies: * Treated with stents other than Supraflex Cruz or Ultimaster within 6 months prior to index procedure * Treatment of lesions with stent thrombosis * Treatment of venous or arterial coronary grafts * Treated for stent thrombosis in 12 months prior to index PCI procedure * Treated with a bioresorbable scaffold 3 years before index PCI procedure * Cardiogenic shock at index procedure * Active SARS-CoV-2 infection or suspicion of SARS-CoV-2 infection * Cannot provide written informed consent * Under judicial protection, tutorship or curatorship * Unable to understand and follow study-related instructions or unable to comply with study protocol * Active bleeding requiring medical attention (BARC≥2) at index PCI * Life expectancy less than one year * Known hypersensitivity or allergy for aspirin, clopidogrel, ticagrelor, prasugrel, cobalt chromium or sirolimus * Any anticipated PCI after index PCI, unless planned and scheduled at index PCI * Participation in another stent or drug trial